Author, year | Study design | Follow-up (years) | No. of eyes/no. of patients | MMC dose (mg/mL) | IOP (mmHg)a | No. of medicationsa | ||
---|---|---|---|---|---|---|---|---|
Baseline | At follow-up | Baseline | At follow-up | |||||
Riss et al. 2015 [12] | Retrospective, two-center, two-surgeon | 1 | 23/23 | 0.4 near limbus | 23.8 ± 5.3 | 10.7 ± 2.8 | 2.4 ± 0.9 | 0.3 ± 0.8 |
31/31 | 0.2 near limbus | 27.9 ± 6.7 | 13.3 ± 3.3 | 2.5 ± 1.4 | 0.5 ± 1.0 | |||
33/33 | 0.4 deep in pocket | 25.4 ± 7.9 | 15.7 ± 4.6 | 2.9 ± 1.0 | 0.8 ± 1.3 | |||
Batlle et al. 2016 [13] | Single-center case series | 3 | 23/23 | 0.4 | 23.8 ± 5.3 | 10.7 ± 3.5 | 2.4 ± 0.9 | 0.7 ± 1.1 |
Batlle et al. 2021 [14] | Single-center case series | 5 | 23/23 | 0.4 | 23.8 ± 5.3 | 12.4 ± 6.5 | 2.4 ± 1.0 | 0.8 ± 1.3 |
Ahmed et al. 2022 [15] | Single-center, non-randomized | 6 | 8/7 | Not stated | 17.9 ± 3.5 | 13.5 ± 3.1 | 3.5 ± 0.5 | 2.0 ± 1.1 |
Schlenker et al. 2020 [16] | Retrospective case series | 1 | 164/132 | 0.2–0.5 | 20 (IQR 16.5–26) | 12 (IQR 10–15) | 4 (IQR 3–4) | 0 (IQR 0–0) |
Durr et al. 2022 [17] | Retrospective cohort | 1 | 85/79 | Not stated | 22 (IQR 18–29) | 13 (IQR 10–17) | 4 (IQR 3–4) | 0 (IQR 0–2) |
Baker et al. 2021 [18] | Prospective randomized controlled trial | 1 | MicroShunt group 395/395 | 0.2 | 21.1 ± 4.9 | 14.3 ± 4.3 | 3.1 ± 1.0 | 0.6 ± 1.1 |
Trabeculectomy group 132/132 | 0.2 | 21.1 ± 5.0 | 11.1 ± 4.3 | 3.0 ± 0.9 | 0.3 ± 0.9 | |||
Panarelli et al. 2021 [19] | Prospective randomized controlled trial | 2 | MicroShunt group 395/395 | 0.2 | 21.1 ± 4.9 | 13.9 ± 3.9 | 3.1 ± 1.0 | 0.9 ± 1.3 |
Trabeculectomy group 132/132 | 0.2 | 21.1 ± 5.0 | 10.7 ± 3.7 | 2.9 ± 0.9 | 0.4 ± 0.9 | |||
Beckers et al. 2022 [20] | Prospective, multi-center, single-arm | 2 | 81/81 | 0.2–0.4 | 21.7 ± 3.4 | 14.1 ± 3.2 | 2.1 ± 1.3 | 0.5 ± 0.9 |